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Abstract. Background: Adjuvant 5-fluoruracil-based
chemotherapy significantly reduces mortality in patients with
stage II-III colon cancer, but is less prescribed with rising age.
In this study we were interested in the pattern of adjuvant
treatment and possible effects on survival among elderly
patients. Patients and methods: From January to December
2004, 63 questionnaires on the management of stage II-III
resected colon cancer patients aged over 70 years, collected
from 10 Italian Centres, were retrospectively examined.
Determinants of receipt of adjuvant chemotherapy and their
relation to survival were considered. Results: The proportion of
elderly patients receiving adjuvant chemotherapy was 79.4% ,
distinct of age, gender, educational level and comorbidities.
Grade 3-4 toxicities were the following: haematological in 4
(8.5.% ) patients, mucositis in 4 (8.5% ), diarrhoea in 2
(4.2% ) and nausea in 1 (2.1% ). The disease-free survival
(DFS) and overall survival (OS) at two years were 79.9% and
95.6% , respectively. Due to the paucity of events, the impact
of prognostic factors (patient’s age and comorbidity, tumour
stage and grade) on DFS and OS could not be assessed.
Conclusion: An increasing proportion of elderly patients with
colon cancer may be treated with a tolerability and OS similar
to those observed in the younger population. Development of
age-based guidelines and increased awareness of both
physicians and patients through education is important to
prevent undertreatment of those elderly patients who are
eligible for chemotherapy.
The prognosis for elderly patients who have undergone resection
of a stage II-III colon carcinoma remains relatively poor.
Adjuvant treatment has a significant positive effect on both
overall survival (OS) and time to tumour recurrence (p<0.001)
(1). The 5-year OS is in fact 71% for patients receiving adjuvant
therapy, as compared with 64% for those untreated. No
significant interaction is usually observed between age and the
efficacy of treatment (1). Several trials have established 5-
fluorouracil (5-FU)-based chemotherapy as the standard
adjuvant treatment for patients with stage III disease (2-7),
however, retrospective analyses have shown such adjuvant
chemotherapy to be administered less with increasing age.
Moreover, the number of involved nodes, presence of
comorbidity, higher refusal rates among elderly patients, hospital
volume and socioeconomic factors are reported to influence the
administration of adjuvant chemotherapy (1, 8-11).
In order to evaluate the tolerability of treatment in
oncogeriatric patients receiving cancer chemotherapy, the
Authors tried to evaluate the colon cancer care of elderly
people in 10 Italian Oncology Units, determining the
proportion of patients receiving adjuvant chemotherapy even
if in the presence of comorbidities. We assessed factors
associated with receipt of chemotherapy and to what extent
these factors were related to survival.
Patients and Methods
Eligibility criteria. From November 2005 to May 2006, an open
questionnaire concerning, for example, the number of stage II-III
colon cancer patients ≥70 years old in care in 2004, the opinions on
the use of antitumour drugs, haematopoietic growth factors,
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administration methods, family role, type of support required and
patient informed consent was sent to all Medical Oncology Units in
Italy (Table I).
The following patient characteristics were recorded: age at time of
diagnosis, gender and comorbidity, the latter scored according to
Charlson’s classification (12). The questionnaire was forwarded to the
Heads of the Units with an accompanying letter from the past
International Society of Geriatric Oncology (SIOG) President. The
questionnaires were returned in the following 3 months. To send and
get back the completed questionnaire took 40 days. By the fixed
deadline of May 2006, 63 completed files on adjuvant chemotherapy
in stage II-III colon adenocarcinoma forms were collected for analysis.
Colon tumours were defined as C18.0–C18.7 according to
International Classification of Diseases for Oncology, Third Edition
(ICD-O-3). The following tumour characteristics were recorded:
tumour grade (low grade, well- or moderately differentiated, versus
high grade, poorly or undifferentiated tumours), postoperative extent
of disease (T1/T2, T3, T4) and lymph node involvement (N1, N2).
The stage II patients were classified into two subgroups (IIA, T3N0;
IIB, T4N0); the stage III patients were classified into three
subgroups (IIIA, any T1-2/N1; IIIB, T3-4/N1; IIIC, any T/N2)
according to the International Union Against Cancer (UICC) TNM
Classification of Malignant Tumours (sixth edition) (13).
Adjuvant chemotherapy (yes versus no and reasons for
administration in addition to information on type and dose were
available) and hospitals where treatment was administered were also
recorded.
The status of all patients was assessed by phone interviews or by
consultation with Municipal registries.
Statistical analysis. Patient numbers were compared for categorical
variables by means of chi-squared test (with Fisher’s exact
correction for frequencies less than 5). Variables tested for the
choice of chemotherapy were gender, age ≤75 versus >75 years,
Charlson’s score (0 versus 1-4), tumor stage and tumor grade (G1-
2 versus G3). Progression was measured from time of surgery to
first evidence of local/systemic relapse or death for any cause, while
survival was measured from time of surgery to death for any cause.
Disease-free survival (DFS) and OS were estimated by means of
the Kaplan-Meier method using Statistica software, version 6
(Statsoft, Inc., Tulsa, OK, USA). Prognostic factors for DFS and
OS were tested by means of log-rank test.
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Table I. Questions in the questionnaire.
General
Medical Unit
Patient-related
General background
Educational level
Profession
Physical characteristics
Date of birth
Weight
Height
Disease-related characteristics of patient
Blood value of albumin and creatinine
Creatinine clearance
Symptoms at diagnosis
Intestinal function
First appearance
Multidimensional Geriatric Assessment (MGA)
Performance Status (PS)
Activity of Daily Living (ADL)
Instrumental of Activity Of Daily Living (IADL)
Mental Status (MMS)
Depressive Geriatric Symptoms (GDS)
Comorbidities according to Charlson’s classification
Disease-related
Surgery
Surgery of the primitive lesion and number of resected nodes
Patient’s agreement to surgery
Disease characteristics
Date of diagnosis
Site
Stage
Grading
Macroscopic feature
Vascular involvement
Lymphatic involvement
Adjuvant treatment
Indication and reasons
Was chemotherapy suggested by the doctor?
Patient informed about disease
Comorbidities adequacy to therapy
PS adequacy to therapy
Cognitive functioning adequacy to therapy
Family involvement in the patient’s life
Family agreement to adjuvant chemotherapy
Adequate logistic support
Chemotherapy administered and reasons why
Precocious interruption and causes
Number of cycles
Before any cycle:
- patient PS
- weight
- body surface
- blood value of albumin, creatinine and cholesterol
- creatinine clearance
- delay of dose administration
- dose reduction and cause
- maximal toxicity, neurotoxicity, febrile neutropenia
- granulocyte growth factors administration
- erithropoietic growth factors administration
- hospital admission, time and causes
Two months after the end of treatment:
- patient PS
- weight
- MGA
- personal experience of chemotherapy
- late toxicity
- relapse local or systemic
- date of relapse
- site and number of metastases
Patient status
Results
Ten out of 50 Medical Oncology Units in Italy answered.
Patient characteristics. Sixty-three elderly patients radically
resected for colon cancer were identified, with a median age of
76 years (range 70-84 years). Their characteristics are outlined
in Table II. Twenty-one patients (33.4% ) were asymptomatic
at the time of diagnosis, while 11 had anaemia and/or rectal
bleeding (17.4% ), 22 abdominal pain and/or constipation
(34.9% ) and 9 had acute complications requiring urgent
hospital admission (14.3% ). The median creatinine clearance
value was 50 ml/min (range 28-97 ml/min). Only 12 patients
had been evaluated by means of Multidimensional Geriatric
Assessment. Only 1 patient was dependent for one or more
Activity Daily Living (ADLs, ability to carry out common
daily activities such as washing, dressing, eating, moving), 3
patients were dependent on one or more Instrumental Activity
Daily Living (IADLs, ability to carry out common
instrumental daily activities such as using money, phone or
transport, cleaning, doing the shopping, taking medication)
and 10 had a Mini Mental State (MMSE) score >24; 8
patients reported a Geriatric Depression Scale (GDS) <5.
Fifteen patients did not have any concomitant disease,
while the distribution according to Charlson’s score is
outlined in Table II.
Choices concerning adjuvant chemotherapy. According to the
treating oncologist, an indication for adjuvant chemotherapy
was present in 58 patients, but in 8 cases treatment was not
started due either to the patient’s refusal (4 patients), family
interference, or inadequate support (4 patients). Treatment
was promptly accepted by the majority of the 50 treated
patients, but a prolonged discussion with the patient to
circumvent initial reluctance was required in 6 cases (12% ).
Since adjuvant chemotherapy was started in 14 (53.8% )
stage II patients and in 36 stage III patients (97.3% , p=0.001),
the involvement of lymph nodes was confirmed as the most
relevant adverse prognostic parameter for actual administration
of such treatment. Moreover, among the 26 patients with stage
II colon cancer, administration of adjuvant chemotherapy
increased according to T stage (50% of patients in T3N0 versus
71.4% of patients in T4N0, p=0.26) but data were not
significantly different (Table III). Males had a nonsignificant
trend for an increased percentage of N+ disease (66.7 versus
41.1% , p=0.14) and the prescription of adjuvant chemotherapy
(83.1% versus 74.1% , p=0.37). Prescription of adjuvant
chemotherapy did not correlate either with age ≤75 versus >75
years (86.7% versus 72.7% , p=0.17) or with performance
status (PS) 0 versus 1-2 (81.8% versus 71.0% , p=0.72).
Positive lymph nodes were present in approximately half
of both subgroups of grade 1-2 and grade 3 tumour patients
(55 versus 56.5% , p=0.9), with almost equal percentages of
prescription of adjuvant treatment (77.5% in grade 1-2
versus 82.6% in grade 3, p=0.63).
Chemotherapy was administered independently of
Charlson’s grade of comorbidity (50% of patients without
comorbidity score 0 versus 63.6% of patients score 1 to 4,
p=0.21); 69.2% of patients who did not undergo
chemotherapy had a Charlson’s grade 0.
Type, duration and toxicity of adjuvant chemotherapy. The
chemotherapy regimen was based on a combination of 5-FU
and folinic acid, with the addition of oxaliplatin in only 5
patients. The mean number of cycles was 5.18 (range 1 to 6).
Grade 3-4 toxicities were: haematological in 4 (8.5.% )
patients, mucositis in 4 (8.5% ), diarrhoea in 2 (4.2% ) and
nausea in 1 (2.1% ). Granulocytic growth factors were
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Table II. Patient characteristics (N=63).
No. %
Median age (range)
76 years (70-84)
Age group (years)
≥70 to 75 30 47.6
>75 to 84 33 52.4
Gender
Male 36 57.2
Female 27 42.8
Performance status (PS)
0 22 35.0
1 36 57.1
2 4 6.3
3 1 1.6
Comorbidities
(Charlson’s grade)
0 34 54.0
1 17 27.0
2 3 4.8
3 7 11.0
4 2 3.2
Symptoms
Yes 42 66.7
No 21 33.3
Site of primary lesion
Sigma 20 31.7
Colon 39 61.9
Cecum 4 6.4
Stage of colon disease
II A 19 30.1
B 7 11.1
III A 5 8.0
B 18 28.6
C 14 22.2
Grading of tumour
1 2 3.2
2 38 60.3
3 23 36.5
employed in 1 patient, while erythropoietin was administered
to 4 patients. There were no episodes of neutropenic fever
and no toxic deaths. Heterogeneity of regimens, dosages and
incidence of dose reductions does not allow an objective
comparison of toxicity according to age, PS and comorbidity
score of the patients.
Early interruption of chemotherapy was reported in 14
patients (28% ). Treatment-related toxicities were the main
cause (11 patients, 78.6% ), followed by patient refusal (2
patients) and progression (1 patient). Toxicity-related
interruption did not appear to be related to age (5/26 patients
≤75 years old and 6/24 patients >75 years old, p=0.62) or
Charlson’s score (5/25 with score 0 and 6/25 with score ≥1,
p=0.73).
Overall, 34 patients (68% ) gave a positive rating for the
subjective experience of chemotherapy (Table IV).
Time to progression and survival. At the end of May 2006,
follow-up data were available for 54 patients. After a median
follow-up of 15.1 months, 5 patients had progressed and 2
had died due to the relapsed tumor. Site of relapses were
liver only (2 patients), liver and peritoneum (2 patients) and
liver and subcutaneous (1 patient). Three patients underwent
metastasectomy, one systemic chemotherapy and two were
not treated. The DFS (Figure 1) and OS at two years were
79.9% and 95.6% , respectively.
Due to the paucity of events, the impact of prognostic factors
(patient’s age and comorbidity, tumor stage and grade) on DFS
and OS could not be assessed. Yet all relapsing patients were
N2 (2 pT3 and 3 pT4), none of them was grade 1.
Discussion
In our study of 63 patients aged 70-84 years with stage II-III
colon cancer, we found that adjuvant chemotherapy was
equally administered according to increasing age, gender, PS
and comorbidity level. All patients with more than T3N0
stage of disease underwent therapy.
The chemotherapy schedule choice was not influenced by
inter-hospital variation.
Toxicity was comparable with published data on adjuvant
chemotherapy in elderly patients (diarrhoea 4% ; stomatitis
8% ; nausea and vomiting 2% ) and toxicity-related interruption
did not appear to be related to age (p=0.62) or Charlson’s score
(p=0.73). Overall, 68% of patients gave a positive rating to the
subjective experience of chemotherapy (Table IV).
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Table IV. Treatment compliance within 50 patients who underwent
adjuvant chemotherapy.
No. %
Tolerability
Good 26 52
Very good 8 16
Bad 6 12
Very bad 10 20
Table III. Characteristics of 50 elderly patients who underwent adjuvant
chemotherapy.
Characteristic No %
Gender
Male 30 64
Female 20 36
Performance status (PS)
0 18 36
1 31 62
2 1 2
Comorbidities (Charlson’s grade)
0 25 50
1 15 30
2 2 4
3 6 12
4 2 4
Stage of colon disease
II A 9 18
B 5 10
III A 5 10
B 18 36
C 13 26
Grading of tumour
1 2 4
2 29 58
3 19 38
Figure 1. Disease free survival in 54 evaluable patients (5 events, 49
censored). (duration of survival, months).
The lower probability of receiving adjuvant treatment for
elderly patients with colon cancer has already been shown
(8, 9, 14-18). The reason why these patients are less likely to
receive adjuvant treatment is multifactorial. In addition to the
presence of concomitant diseases, more patient refusal
among the elderly, the absence of supportive caregivers, a
decrease in the patients’ general condition, especially frailty
and cognitive abilities, could result in lower chemotherapy
rates (10, 19-22). Referral to medical oncology is also one of
the most important factors associated with reception of
chemotherapy among older patients with stage III colon
cancer. Ensuring that high-risk patients are referred to
medical oncology is also a crucial step in quality care for
patients with colon cancer (11).
Most of the available studies present evidence of tolerance
and efficacy of chemotherapy among both selected and
unselected elderly colon cancer patients (8, 10, 15, 23, 24),
thus counteracting the persisting ‘ageism’ in colon cancer
care. However, there are probably still uncertainties about the
risk–benefit ratio of aggressive treatment, as is sometimes
suggested by the observed inter-hospital variation (25).
Despite the reported similar tolerance among males and
females for 5-FU-based chemotherapy, the higher refusal
rate among elderly women may partly be responsible for the
finding that the latter were less likely to receive adjuvant
treatment (9, 26, 27).
Patients presenting with comorbidities received adjuvant
chemotherapy like the other patients, in contradiction with
previous retrospective clinical studies (9, 10, 17, 18). Few
prospective studies have reported the effect of comorbidity
on the safety and efficacy. Our results underline that Italian
oncologists are not influenced by comorbidities in their
decision-making and this could be an important sign that
elderly patients in some centres are not undertreated as often
appears in the literature data. On the other hand, only 12
patients had been evaluated by means of Multidimensional
Geriatric Assessment; in fact a Multidimensional Geriatric
Assessment could be more useful for analyzing single
patients and problems better.
Patients with stage IIIB disease (T3–4, N1) received
adjuvant chemotherapy as stage IIIC disease (any T, N2); also
in this case, the treatment choice was not influenced by age.
Because of the low number of events, it is not possible to
say if adjuvant chemotherapy had a marked independent
prognostic impact (18, 23). Due to the population-based
nature of our data, we do not know the extent to which this
positive prognostic impact was caused by selecting the ‘fitter’
patients for adjuvant chemotherapy, or by other factors (6).
Our finding that patients aged 70 or older had a better
prognosis than patients aged 65-69 years is odd, but in line
with the results of a large single-hospital study where patients
with stage III colon cancer aged 65 years or older had an
overall 5-year survival of 74% , compared to 54% for patients
younger than 65 years (28). A possible explanation for this
finding might be a selection of the more robust individuals
living long enough to develop colon cancer, or a potential
decrease in aggressiveness of the tumour with rising age.
Data extraction from the patient’s medical record is
regarded as the most complete source of information on the
patient’s past and current health status (29). All except two
patients with PS ≥2 did not undergo therapy; all the others
had a PS of 1. Performance score and comorbidity are
usually both predictive factors of treatment and survival for
cancer patients, independent of each other (30, 31).
However, PS often depends on malignant disease and its
treatment, in contrast to comorbidity. In this case, among all
patients not undergoing therapy, only one had a Charlson’s
comorbidity grade 3 (and PS 1), another a grade 2 (and PS
2) and another one a grade 1 (and PS 2).
Although the proportion of elderly patients with colon
cancer receiving adjuvant chemotherapy is increasing, many
elderly patients still do not receive or accept this treatment.
A total of 13.8% of patients did not undergo chemotherapy
due to the patient’s refusal (50% of cases), or family
interference (50% of cases). In 6 cases (12% ), a prolonged
discussion with the patient to circumvent initial reluctance was
also required. Devoting time to the relatives may also
represent a key element in creating a communicative and
efficient relationship with older cancer patients (32).
Conclusion
In this everyday setting, results confirm the experience
from large multicentric studies: stage III patients are
offered adjuvant chemotherapy on a regular basis, while
around only 50% of stage II patients are treated. A trend
towards treatment in younger and fitter patients or those
with T4 tumours was found. Because of the very short
follow-up and small sample size, the value of survival
curves might be questioned.
Development of age-based guidelines and increased
awareness of both physicians and patients through education is
important to prevent undertreatment of (subgroups of) elderly
patients who are eligible for chemotherapy. With decision
making becoming more individualised with rising age, the use
of a comprehensive geriatric assessment may be helpful in
choosing the most adequate treatment for these patients.
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